318 related articles for article (PubMed ID: 30222359)
1. Synergistic Targeting HER2 and EGFR with Bivalent Aptamer-siRNA Chimera Efficiently Inhibits HER2-Positive Tumor Growth.
Xue L; Maihle NJ; Yu X; Tang SC; Liu HY
Mol Pharm; 2018 Nov; 15(11):4801-4813. PubMed ID: 30222359
[TBL] [Abstract][Full Text] [Related]
2. Targeting EGFR/HER2/HER3 with a Three-in-One Aptamer-siRNA Chimera Confers Superior Activity against HER2
Yu X; Ghamande S; Liu H; Xue L; Zhao S; Tan W; Zhao L; Tang SC; Wu D; Korkaya H; Maihle NJ; Liu HY
Mol Ther Nucleic Acids; 2018 Mar; 10():317-330. PubMed ID: 29499944
[TBL] [Abstract][Full Text] [Related]
3. Aptamer-functionalized hybrid nanoparticle for the treatment of breast cancer.
Powell D; Chandra S; Dodson K; Shaheen F; Wiltz K; Ireland S; Syed M; Dash S; Wiese T; Mandal T; Kundu A
Eur J Pharm Biopharm; 2017 May; 114():108-118. PubMed ID: 28131717
[TBL] [Abstract][Full Text] [Related]
4. Development of HER2-Specific Aptamer-Drug Conjugate for Breast Cancer Therapy.
Jeong HY; Kim H; Lee M; Hong J; Lee JH; Kim J; Choi MJ; Park YS; Kim SC
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33371333
[TBL] [Abstract][Full Text] [Related]
5. Disulfide bond disrupting agents activate the unfolded protein response in EGFR- and HER2-positive breast tumor cells.
Ferreira RB; Wang M; Law ME; Davis BJ; Bartley AN; Higgins PJ; Kilberg MS; Santostefano KE; Terada N; Heldermon CD; Castellano RK; Law BK
Oncotarget; 2017 Apr; 8(17):28971-28989. PubMed ID: 28423644
[TBL] [Abstract][Full Text] [Related]
6. Co-targeting EGFR and survivin with a bivalent aptamer-dual siRNA chimera effectively suppresses prostate cancer.
Liu HY; Yu X; Liu H; Wu D; She JX
Sci Rep; 2016 Jul; 6():30346. PubMed ID: 27456457
[TBL] [Abstract][Full Text] [Related]
7. A neutralizing RNA aptamer against EGFR causes selective apoptotic cell death.
Esposito CL; Passaro D; Longobardo I; Condorelli G; Marotta P; Affuso A; de Franciscis V; Cerchia L
PLoS One; 2011; 6(9):e24071. PubMed ID: 21915281
[TBL] [Abstract][Full Text] [Related]
8. Ibrutinib Inhibits ERBB Receptor Tyrosine Kinases and HER2-Amplified Breast Cancer Cell Growth.
Chen J; Kinoshita T; Sukbuntherng J; Chang BY; Elias L
Mol Cancer Ther; 2016 Dec; 15(12):2835-2844. PubMed ID: 27678331
[TBL] [Abstract][Full Text] [Related]
9. Targeted dual degradation of HER2 and EGFR obliterates oncogenic signaling, overcomes therapy resistance, and inhibits metastatic lesions in HER2-positive breast cancer models.
Yang L; Bhattacharya A; Peterson D; Li Y; Liu X; Marangoni E; Robila V; Zhang Y
Drug Resist Updat; 2024 May; 74():101078. PubMed ID: 38503142
[TBL] [Abstract][Full Text] [Related]
10. An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression.
Schwarz LJ; Hutchinson KE; Rexer BN; Estrada MV; Gonzalez Ericsson PI; Sanders ME; Dugger TC; Formisano L; Guerrero-Zotano A; Red-Brewer M; Young CD; Lantto J; Pedersen MW; Kragh M; Horak ID; Arteaga CL
J Natl Cancer Inst; 2017 Nov; 109(11):. PubMed ID: 29059433
[TBL] [Abstract][Full Text] [Related]
11. Chloroquine in combination with aptamer-modified nanocomplexes for tumor vessel normalization and efficient erlotinib/Survivin shRNA co-delivery to overcome drug resistance in EGFR-mutated non-small cell lung cancer.
Lv T; Li Z; Xu L; Zhang Y; Chen H; Gao Y
Acta Biomater; 2018 Aug; 76():257-274. PubMed ID: 29960010
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic siRNA for drug-resistant HER2-positive breast cancer.
Gu S; Hu Z; Ngamcherdtrakul W; Castro DJ; Morry J; Reda MM; Gray JW; Yantasee W
Oncotarget; 2016 Mar; 7(12):14727-41. PubMed ID: 26894975
[TBL] [Abstract][Full Text] [Related]
13. Novel Hsp90 inhibitor FW-04-806 displays potent antitumor effects in HER2-positive breast cancer cells as a single agent or in combination with lapatinib.
Huang W; Wu QD; Zhang M; Kong YL; Cao PR; Zheng W; Xu JH; Ye M
Cancer Lett; 2015 Jan; 356(2 Pt B):862-71. PubMed ID: 25449780
[TBL] [Abstract][Full Text] [Related]
14. Delivery of chemo-sensitizing siRNAs to HER2+-breast cancer cells using RNA aptamers.
Thiel KW; Hernandez LI; Dassie JP; Thiel WH; Liu X; Stockdale KR; Rothman AM; Hernandez FJ; McNamara JO; Giangrande PH
Nucleic Acids Res; 2012 Jul; 40(13):6319-37. PubMed ID: 22467215
[TBL] [Abstract][Full Text] [Related]
15. HER2-siRNA delivered by EGFR-specific single chain antibody inhibits NSCLC cell proliferation and tumor growth.
Lu Y; Wang Y; Zhang M; Liu L; Li F; Zhang J; Ye M; Zhao H; Zhao J; Yan B; Yang A; Zhang R; Li X; Ren X
Oncotarget; 2016 Apr; 7(17):23594-607. PubMed ID: 26988752
[TBL] [Abstract][Full Text] [Related]
16. Combining AZD8931, a novel EGFR/HER2/HER3 signalling inhibitor, with AZD5363 limits AKT inhibitor induced feedback and enhances antitumour efficacy in HER2-amplified breast cancer models.
Crafter C; Vincent JP; Tang E; Dudley P; James NH; Klinowska T; Davies BR
Int J Oncol; 2015 Aug; 47(2):446-54. PubMed ID: 26095475
[TBL] [Abstract][Full Text] [Related]
17. Dual silencing of EGFR and HER2 enhances the sensitivity of gastric cancer cells to gefitinib.
Wang L; Zhang H; Zheng J; Wei X; Du J; Lu H; Sun Q; Zhou W; Zhang R; Han Y
Mol Carcinog; 2018 Aug; 57(8):1008-1016. PubMed ID: 29637613
[TBL] [Abstract][Full Text] [Related]
18. Effects of the EGFR/HER2 kinase inhibitor GW572016 on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance.
Zhou H; Kim YS; Peletier A; McCall W; Earp HS; Sartor CI
Int J Radiat Oncol Biol Phys; 2004 Feb; 58(2):344-52. PubMed ID: 14751502
[TBL] [Abstract][Full Text] [Related]
19. Antibody targeting facilitates effective intratumoral siRNA nanoparticle delivery to HER2-overexpressing cancer cells.
Palanca-Wessels MC; Booth GC; Convertine AJ; Lundy BB; Berguig GY; Press MF; Stayton PS; Press OW
Oncotarget; 2016 Feb; 7(8):9561-75. PubMed ID: 26840082
[TBL] [Abstract][Full Text] [Related]
20. (-)-Oleocanthal Combined with Lapatinib Treatment Synergized against HER-2 Positive Breast Cancer In Vitro and In Vivo.
Siddique AB; Ebrahim HY; Akl MR; Ayoub NM; Goda AA; Mohyeldin MM; Nagumalli SK; Hananeh WM; Liu YY; Meyer SA; El Sayed KA
Nutrients; 2019 Feb; 11(2):. PubMed ID: 30781364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
